HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Clinical trials for HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to control advanced breast cancer
Disease control Recruiting nowThis study tests a drug called alisertib combined with hormone therapy for people with a common type of advanced breast cancer (HR+, HER2-). The cancer has continued to grow despite at least two prior hormone treatments. The goal is to find the best dose of alisertib and see if t…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Puma Biotechnology, Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
New hope for Hard-to-Treat breast cancer: targeted drug trial begins
Disease control Recruiting nowThis early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New hope for tough breast cancer: experimental drug EP0062 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called EP0062, alone or with standard treatments, in people with a certain type of advanced breast cancer (AR+/HER2-) that has returned or spread. The main goals are to find the safest dose and see if it helps shrink tumors. About 95 adults a…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Ellipses Pharma • Aim: Disease control
Last updated Jun 12, 2026 12:05 UTC
-
New combo pill aims to extend life for BRCA breast cancer patients
Disease control Recruiting nowThis study tests whether adding the oral drug elacestrant to standard olaparib can help people with HR-positive, HER2-negative advanced breast cancer who have BRCA1/2 mutations. About 176 participants will be randomly assigned to receive either the combination or olaparib alone. …
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: GBG Forschungs GmbH • Aim: Disease control
Last updated Jun 09, 2026 12:09 UTC
-
New triple-drug attack on breast cancer enters human testing
Disease control Recruiting nowThis study tests a new drug (VS-6766) combined with two standard treatments (abemaciclib and fulvestrant) for people with advanced HR+/HER2- breast cancer that has spread. The goal is to find the safest dose and see if the combination helps shrink or control the cancer. About 63 …
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Adrienne G. Waks • Aim: Disease control
Last updated Jun 08, 2026 13:18 UTC
-
Could your period affect breast cancer treatment? new study investigates.
Knowledge-focused Recruiting nowThis study looks at women with early-stage, hormone-positive breast cancer to see if the phase of their menstrual cycle changes a key growth marker called Ki67. Researchers will also check if adding a genetic test (PAM50) helps doctors choose better treatments. About 504 women wi…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Sponsor: University Hospital Tuebingen • Aim: Knowledge-focused
Last updated Jun 15, 2026 18:56 UTC